The risk of cardiovascular (CV) disease (CVD) is significantly higher among patients with rheumatoid arthritis (RA) than those with type 2 diabetes (T2D), results of the CARRÉ* study reveal. Such risk persisted even after adjusting for traditional CV risk factors, which suggests that systemic inflammation is an independent contributor to CV risk.
Treatment with denosumab in patients with osteoporosis and diabetes yields a substantial increase in bone mineral density (BMD) and a reduction in the risk of vertebral, but not nonvertebral, fractures, a study has found.
Postmenopausal women with vitamin D deficiency are at greater odds of having lumbar disc degeneration (LDD) and low back pain (LBP), with a serum vitamin D concentration of <10 ng/mL being a marker of severe LDD and LBP, as reported in a recent study.
A long-term course of once-weekly tocilizumab in patients with Takayasu arteritis appears to exert a steroid-sparing effect and yields improvements in well-being without raising new safety concerns, according to data from the Takayasu Arteritis Treated with Tocilizumab trial.
Rheumatoid arthritis (RA) patients who exhibit low rheumatoid factor (RF), as well as low disease activity, following treatment with certolizumab pegol (CZP) plus methotrexate (MTX) may be able to discontinue CZP without the increased risk of loss of remission, a recent study has shown.
The development of scleroderma renal crisis (SRC), a severe life-threatening complication in patients with systemic sclerosis (SSc), is rare, but its highest risk is associated with the detection of anti-RNA polymerase antibodies (RNAP) and proteinuria, suggests a recent study.
Experts worldwide support the updated recommendations for the treatment of systemic sclerosis (SSC) as shown by their high agreement, reports a study. Differences in agreement are partially due to geographical area and treatment availability.
A higher prednisolone dose results in a marked reduction in the relapse rate among patients with Takayasu arteritis (TA), reveals a recent study. Moreover, lower-dose prednisolone monotherapy appears to be a disadvantageous strategy for remission induction in TA despite low disease activity.
Men with systemic lupus erythematosus (SLE) are more likely to develop coronary artery calcifications (CAC) than age- and sex-matched controls, a recent study has shown. Such risk among patients with SLE is associated with older age, increasing chronic damage and cumulative dose of corticosteroids.